3 completed, 1 recruiting. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Recruiting 1 |
Follow Placebo-Matching Ubrogepant: new trials by email Literature Review of Placebo-Matching Ubrogepant trials Research Report on Placebo-Matching Ubrogepant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) Ubrogepant, Placebo-Matching Ubrogepant - Migraine | Phase 3 | Recruiting | AbbVie | 1059 | 2022-01-13 | 2026-09-14 |
| An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine Ubrogepant, Placebo-matching Ubrogepant, Usual Care - Migraine, With or Without Aura | Phase 3 | Completed | Allergan | 1254 | 2016-09-13 | 2019-08-28 |
| Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine Ubrogepant, Placebo-matching Ubrogepant - Migraine, With or Without Aura | Phase 3 | Completed | Allergan | 1686 | 2016-08-26 | 2019-03-19 |
| Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine Ubrogepant, Placebo-matching Ubrogepant - Migraine, With or Without Aura | Phase 3 | Completed | Allergan | 1672 | 2016-07-22 | 2019-01-03 |
United States (4) · Puerto Rico (1)
Adele Thorpe (3)
PMID 34874514, PMID 33241721, PMID 33608814, PMID 33874756, PMID 35468729, PMID 36125279, PMID 39982105, PMID 31742631, PMID 31800988, PMID 35977836